PubMed Health⌕ Search

Biomedical subjects

A J Girgenti

Publications and source records attributed to A J Girgenti.

6 recordsLinked to original sources
PubMed1976

Inhibition of transfer ribonucleic acid nucleotidyl transferase (EC 2.7.7.25) from Ehrlich tumor cells by proflavine sulfate and ethidium bromide.

Transfer RNA nucleotidyl transferase from Ehrlich tumor cells was inhibited by proflavine sulfate and ethidium bromide but not by actinomycin D, chromomycin, rifamycin SV, rifampin, daunomycin, or alpha-amanitin. Complete inhibition of nucleotidyl transferase activity was attained at a final concentration of 1 mmol/1 proflavine sulfate, while 2 mmol/1 ethidium bromide was required to completely inhibit the enzyme. CMP incorporation into tRNA was more sensitive to both proflavine sulfate and ethidium bromide than was AMP incorporation.

Acridines↗
PubMedDate not supplied

Assessment of results of estrogen and progesterone receptor assays performed in a community hospital.

Approximately 1,000 assays for estrogen receptor (ER) in primary human breast tumors have been performed at St. Joseph's Hospital over a period of seven years; 700 of these included assays for progesterone receptor (PR). Based on the method of analysis (dextran-coated charcoal) and criteria for a positive result used for this survey, 80 percent of the primary tumors were ER-positive and 56 percent were PR-positive. In those cases where both assays were performed, 47.4 percent were ER-positive, PR-positive; 19.8 percent were ER-positive, PR-negative; 6.2 percent were ER-negative, PR-positive; and 26.6 percent were ER-negative, PR-negative. The mean concentration of ER increased with the advancing age of the patient; essentially the same relationship was observed for PR. The concentration of ER and PR was not directly dependent upon the degree of cellularity of the tumor. Lobular carcinoma and the mixed types containing ductal and lobular elements had the highest frequency of being positive for both steroid receptors, while medullary and papillary carcinomas were lowest. Three hundred and twenty-two cases had follow-up studies and were examined on the basis of the available information in the files of St. Joseph's Hospital Tumor Registry. A higher survival rate in patients with both ER and PR positivity became evident. In a community hospital setting, our data confirm the usefulness of estrogen and progesterone receptor assays in decisions of clinical management and considerations of prognosis in patients with mammary carcinoma.

Adult↗
PubMedDate not supplied

Gene rearrangements in malignant lymphomas.

The use of molecular methods to diagnose malignant lymphoma, while firmly established in reference centers, has not been well evaluated at the community level. A group of 57 specimens from patients with non-Hodgkin's lymphomas (NHL), lymphoid leukemias (LL), and a variety of other lymphoproliferative lesions with the Southern blot methodology have been studied by us. Molecular probes to the joining regions of the heavy (JH) and light (J kappa) immunoglobulin chains and the beta (J beta 1-2) chain of the T cell receptor genes were used. Gene rearrangements were detected in 90 percent of all NHL/LL with a 95 percent detection rate specifically for B-NHL/LL. In comparison, phenotypic analysis by immunoperoxidase stains favored a B phenotype in 75 percent of those cases, while flow cytometry assigned 63 percent of cases to a B cell lineage. Gene rearrangements were detected in four of six cases of T-NHL for a rate of 67 percent. The six other lymphoproliferative lesions included Hodgkin's disease, Castleman's disease, and a case of lymphoid hyperplasia. No rearrangements were detected in these specimens. The studies allowed development of increased confidence in the diagnosis of NHL/LL on ever smaller specimens. The availability of these studies has also helped establish a priority of handling all specimens so that the most appropriate studies can be performed to yield the most useful diagnostic information.

Gene Rearrangement↗